Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

Phase II, Dose-ranging Study to Evaluate the Efficacy Dose Response and Pharmacokinetics of Intravenous Atorvastatin in Hypercholesterolemic Patients Previously Controlled With Oral Atorvastatin

Open-label study will titrate doses of intravenous atorvastatin and monitor respective LDL-C levels in hypercholesterolemic patients previously controlled on oral atorvastatin.

Inclusion Criteria:

• On stable dose of daily oral atorvastatin for >= 5 weeks (oral atorvastatin may be provided during a lead-in period for subjects not previously taking atorvastatin)
• Stable LDL-C confirmed in the previous 7 to 10 days prior to enrollment into the treatment phase.

Exclusion Criteria:

• History of myopathy or rhabdomyolysis
• Liver disease including current biliary disorders
• Positive for HIV, Hepatitis B or Hepatitis C Virus
• Abuse of alcohol or non-prescribed drugs
• Unstable angina or arrhythmias or a cardiac event in the previous three months
• hypothyroidism, diabetes, or hypertension that is not under control
• pregnant or plans to be pregnant